EUVIMEDEUVIMED entdecken
Crossref

GSH-Responsive Heterodimeric Dual-Targeted Nanomedicine Modulates EMT to Conquer Paclitaxel-Induced Invasive Breast Cancer Metastasis

Ying Chen, Yao Chen, Hong Xu, Jianan Liu, Yan Wang, Yingjie Zeng, Hongyu Chen, Yuening Cao, Chen Sun, Xian Ge, Tingting Zhang, Xiaoke Shi und 5 weitere

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Ying Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 6111…. Hauptthemen laut MEDLINE: Paclitaxel, Breast Neoplasms, Glutathione, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Chengdu Municipal Science and Technology Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paclitaxel (PTX), although effective against primary breast cancer, presents formidable clinical challenges due to severe toxicity and pro-metastatic potential, a critical concern as distant metastasis causes 90% of breast cancer-related deaths. To address these limitations, we designed and prepared a tumor microenvironment-responsive nanoprodrug, PTX-SS-3'HPT@RGD-HA NPs, that engineered RGD peptide-modified hyaluronic acid (HA) nanocarriers encapsulating the antimetastatic 3'-hydroxy pterostilbene (3'HPT) and PTX heterodimer linked by a glutathione (GSH)-cleavable disulfide bond. These nanoparticles targeting CD44 and αvβ receptors overexpressed in aggressive breast cancer cells and synergized enhanced permeability and retention effects with receptor-mediated endocytosis, facilitating superior tumor-specific drug deposition and GSH-activated payload release in vitro and in vivo. Moreover, PTX-SS-3'HPT@RGD-HA NPs achieved excellent tumor growth inhibition while mitigating systemic toxicity and metastatic risks in 4T1 tumor-bearing mice. Mechanistically, 3'HPT counteracted PTX-induced epithelial-mesenchymal transition by downregulating MMP-9/N-cadherin and restoring E-cadherin expression, thereby neutralizing PTX-triggered pro-metastatic effects. This study pioneers a dual-targeted, toxicity-shielding nanoplatform that simultaneously improves therapeutic efficacy and addresses chemotherapy-driven metastasis, offering a revolutionary strategy for managing highly invasive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelBreast NeoplasmsGlutathioneEpithelial-Mesenchymal TransitionNanomedicineAntineoplastic Agents, PhytogenicAnimalsFemaleHumansMiceCell Line, TumorMice, Inbred BALB CNanoparticlesHyaluronic AcidNeoplasm MetastasisDrug CarriersOligopeptides

Substanzen

PaclitaxelGlutathioneAntineoplastic Agents, PhytogenicHyaluronic Acidarginyl-glycyl-aspartic acidDrug CarriersOligopeptides

Autor:innen und Institutionen

  • State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
  • Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610054, China.
  • Hematology Department, The General Hospital of Western Theater Command PLA, Chengdu 610083, China.

ORCID-Profile: Jun Lu

Förderung

  • Science and Technology Department of Sichuan Province
  • Chengdu Municipal Science and Technology Program
  • National Natural Science Foundation of China
  • Central Funds Guiding the Local Science and Technology Development of Sichuan Province
  • 2024 Hospital-managed Research Program of the General Hospital of Western Theater Command PLA
  • Sichuan Outstanding Youth Fund Project

Zitieren

APA

Chen, Y., Chen, Y., Xu, H., Liu, J., Wang, Y., Zeng, Y., Chen, H., Cao, Y., Sun, C., Ge, X., Zhang, T., Shi, X., Cao, X., Liu, Y., Ren, B., Wang, T., & Lu, J. (2025). GSH-Responsive Heterodimeric Dual-Targeted Nanomedicine Modulates EMT to Conquer Paclitaxel-Induced Invasive Breast Cancer Metastasis. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00145

Vancouver

Chen Y, Chen Y, Xu H, Liu J, Wang Y, Zeng Y, et al. GSH-Responsive Heterodimeric Dual-Targeted Nanomedicine Modulates EMT to Conquer Paclitaxel-Induced Invasive Breast Cancer Metastasis. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00145

BibTeX
@article{Chen2025,
  author = {Chen, Ying and Chen, Yao and Xu, Hong and Liu, Jianan and Wang, Yan and Zeng, Yingjie and Chen, Hongyu and Cao, Yuening and Sun, Chen and Ge, Xian and Zhang, Tingting and Shi, Xiaoke and Cao, Xiujun and Liu, Yilan and Ren, Bo and Wang, Tianbao and Lu, Jun},
  title = {GSH-Responsive Heterodimeric Dual-Targeted Nanomedicine Modulates EMT to Conquer Paclitaxel-Induced Invasive Breast Cancer Metastasis},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00145}
}
Kostenlos starten →